Endocrine Neoplasms of the Pancreas

Textbook of Gastroenterology, Fifth Edition

Volumn 2, Issue , 2009, Pages 1875-1920

  Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Clinical features and diagnosis insulinoma; Endocrine neoplasms of pancreas; Endocrine tumors of pancreas; Nonfunctioning pancreatic endocrine tumors; Nonmetastatic disease treatment; Pathology and tumor biology; Tumor localization

Indexed keywords

EID: 77955195609     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303254.ch71     Document Type: Chapter

References (475)

1. Eriksson B, Oberg K. PPomas and nonfunctioning endocrine pancreatic tumors: clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers in Gastrointestinal Research. Basel: Karger, 1995: 208.
2. Alexander HR, Jensen RT. Pancreatic endocrine tumors. In: De Vita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 1548.
3. Eriksson B. Tumor markers for pancreatic endocrine tumors, including chromogranins, HCG-alpha and HCG-beta. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel: Karger, 1995: 121.
4. Jensen RT. Endocrine tumors of the pancreas. In: Yamada T, Alpers DH, Kaplowitz N, et al. (eds) Textbook of Gastroenterology, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2003: 2108.
5. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196.
6. Gullo L, Migliori M, Falconi M, et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 2003; 98: 2435.
7. Rindi G, Bordi C. Aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005; 19: 519.
8. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15.
9. Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF (eds). Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris: John Libbey Eurotext Publishing, 1999: 192.
10. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615.
11. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 1989; 28: 373.
12. Jensen RT, Norton JA. Endocrine neoplasms of the pancreas. In: Yamada T, Alpers DH, Owyang C, et al. (eds). Textbook of Gastroenterology, 3rd edn. Philadelphia: J.B. Lippincott, 1998: 2193.
13. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004; 80(Suppl. 1): 3.
14. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, et al. (eds). The Pancreas: Biology, Pathobiology and Disease, 2nd edn. New York: Raven Press, 1993: 931.
15. Guillausseau PJ, Guillausseau C, Villet R, et al. [Glucagonomas. Clinical, biological, anatomopathological and therapeutic aspects (general review of 130 cases)]. Gastroenterol Clin Biol 1982; 6: 1029.
16. Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome: clinical and pathologic features in 21 patients. Medicine 1996; 75: 53.
17. Frankton S, Bloom SR. Glucagonomas. Clin Gastroenterol 1996; 10: 697.
18. Soga J, Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J HepatoBiliary-Pan 1998; 5: 312.
19. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17: 389.
20. Park SK, O'Dorisio MS, O'Dorisio TM. Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. Clin Gastroenterol 1996; 10: 673.
21. Matuchansky C, Rambaud JC. VIPomas and endocrine cholera: clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers in Gastrointestinal Research. Basel: Karger, 1995: 166.
22. Vinik AI, Strodel WE, Eckhauser FE, et al. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 1987; 14: 263.
23. Sassolas G, Chayvialle JA. GRFomas, somatostatinomas: clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers in Gastrointestinal Research. Basel: Karger, 1995: 194.
24. Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995; 59: 67.
25. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18: 13.
26. Nesi G, Marcucci T, Rubio CA, et al. Somatostatinoma: Clinicopathological features of three cases and literature reviewed. J Gastroenterol Hepatol 2008; 23: 521.
27. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 1813.
28. Jensen RT, Norton JA. Endocrine tumors of the pancreas. In: Yamada T, Alpers BH, Owyang C, et al. (eds). Textbook of Gastroenterology, 2nd edn. Philadelphia: J.B. Lippincott, 1995: 2131.
29. Kent RB, Van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg 1981; 193: 185.
30. Hochwald SN, Conlon KC, Brennan MF. Nonfunctional pancreatic islet cell tumors. In: Doherty GM, Skogseid B (eds). Surgical Endocrinology. Philadelphia: Lippincott Williams & Wilkins, 2001: 361.
31. Fleury A, Flejou JF, Sauvanet A, et al. Calcitonin-secreting tumors of the pancreas: about six cases. Pancreas 1998; 16: 545.
32. Langer P, Bartsch D, Gerdes B, et al. Renin producing neuroendocrine pancreatic carcinoma -a case report and review of the literature. Exp Clin Endocrinol Diabetes 2002; 110: 43.
33. Samyn I, Fontaine C, Van Tussenbroek F, et al. Paraneoplastic syndromes in cancer: Case 1. Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor. J Clin Oncol 2004; 22: 2240.
34. Piaditis G, Angellou A, Kontogeorgos G, et al. Ectopic bioactive luteinizing hormone secretion by a pancreatic endocrine tumor, manifested as luteinized granulosa-thecal cell tumor of the ovaries. J Clin Endocrinol Metab 2005; 90: 2097.
35. Brignardello E, Manti R, Papotti M, et al. Ectopic secretion of LH by an endocrine pancreatic tumor. J Endocrinol Invest 2004; 27: 361.
36. Kawano K, Ushijima K, Fujimoto T, et al. Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. J Obstet Gynaecol Res 2007; 33: 392.
37. Matsuda K, Maehama T, Kanazawa K. Strumal carcinoid tumor of the ovary: a case exhibiting severe constipation associated with PYY. Gynecol Oncol 2002; 87: 143.
38. Utsumi N, Hayasaka T, Motoyama T. Ovarian carcinoid exhibiting double function. Pathol Int 2003; 53: 191.
39. Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004; 80(Suppl. 1): 12.
40. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004; 89: 1934.
41. Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 2007; 92: 1118.
42. Langley K. The neuroendocrine concept today. Ann N Y Acad Sci 1994; 733: 1.
43. Heitz PU, Kasper M, Polak JM, Kloppel G. Pancreatic endocrine tumors. Hum Pathol 1982; 13: 263.
44. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 1988; 319: 605.
45. Chiang HC, O'Dorisio TM, Huang SC, et al. Multiple hormone elevations in patients with Zollinger-Ellison syndrome: Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology 1990; 99: 1565.
46. Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B (eds). Surgical Endocrinology: Clinical Syndromes. Philadelphia: Lippincott Williams & Wilkins, 2001: 291.
47. Jensen RT, Norton JA. Endocrine neoplasms of the pancreas. In: Yamada T, Alpers DH, Owyang C, et al. (eds). Textbook of Gastroenterology, 1st edn. Philadelphia: J.B. Lippincott, 1991: 1912.
48. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622.
49. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 1967.
50. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hyper-secretion. Curr Gastroenterol Rep 2004; 6: 454.
51. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 33.
52. Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007; 14: 473.
53. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145.
54. Goebel SU, Serrano J, Yu F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer 1999; 85: 1470.
55. Kahn CR, Rosen SW, Weintraub BD, et al. Ectopic production of chorionic gonadotropin and its subunits by islet-cell tumors. A specific marker for malignancy. N Engl J Med 1977; 297: 565.
56. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102.
57. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395.
58. Bordi C, D'Adda T, Azzoni C, et al. Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol 2006; 17: 119.
59. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 1989; 18: 831.
60. Soga J, Yakuwa Y, Osaka M. Insulinomas/hypoglycemic syndrome: a statistical evaluation of 1085 reported cases of a Japanese series. J Exp Clin Cancer Res 1998; 17: 379.
61. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637.
62. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998; 16: 1040.
63. Calender A. New insights in genetics of digestive neuroendocrine tumors. In: Mignon M, Colombel JF (eds). Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris: John Libbey Eurotext, 1999: 155.
64. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis 2002; 34: 668.
65. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21: 1.
66. Alexakis N, Connor S, Ghaneh P, et al. Hereditary pancreatic endocrine tumours. Pancreatology 2004; 4: 417.
67. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med 2007; 58: 253.
68. Levy-Bohbot N, Merle C, Goudet P, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004; 28: 1075.
69. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404.
70. Debelenko LV, Zhuang ZP, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia typeI-associated sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997; 57: 2238.
71. Goebel SU, Heppner C, Burns AD, et al. Genotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab 2000; 85: 116.
72. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine 2004; 83: 43.
73. Roy P, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000; 79: 379.
74. Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124: 1050.
75. Stefanini P, Carboni M, Patrassi N, Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1067 cases. Surgery 1974; 75: 597.
76. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19: 783.
77. Service FJ. Insulinoma and other islet-cell tumors. Cancer Treat Res 1997; 89: 335.
78. de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183.
79. Guillausseau PJ, Guillausseau-Scholer C. Glucagonomas: clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers in Gastrointestinal Research. Basel: Karger, 1995: 183.
80. O'Toole D, Salazar R, Falconi M, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189.
81. Capella C, Polak JM, Buffa R, et al. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer 1983; 52: 1860.
82. Long RG, Bryant MG, Mitchell SJ, et al. Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas). Br Med J (Clin Res Ed) 1981; 282: 1767.
83. Boden G, Shimoyama R. Somatostatinoma. In: Cohen S, Soloway RD (eds) Hormone-Producing Tumors of the Gastrointestinal Tract. New York: Churchill Livingstone, 1985: 85.
84. Losa M, von Werder K. Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Clin Endocrinol 1997; 47: 123.
85. Soga J. Carcinoids of the pancreas: an analysis of 156 cases. Cancer 2005; 104: 1180.
86. Mao C, Carter P, Schaefer P, et al. Malignant islet cell tumor associated with hypercalcemia. Surgery 1995; 117: 37.
87. Wu TJ, Lin CL, Taylor RL, et al. Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc 1997; 72: 1111.
88. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986; 315: 1.
89. Becker M, Aron DC. Ectopic ACTH syndrome and CRH-mediated Cushing's syndrome. Endocrinol Metab Clin North Am 1994; 23: 585.
90. Raddatz D, Horstmann O, Basenau D, et al. Cushing's syndrome due to ectopic adrenocorticotropic hormone production by a non-metastatic gastrinoma after longterm conservative treatment of Zollinger-Ellison syndrome. Ital J Gastroenterol Hepatol 1998; 30: 636.
91. Chagnon JP, Barge J, Henin D, Blanc D. [Recklinghausen's disease with digestive localizations associated with gastric acid hypersecretion suggesting Zollinger-Ellison syndrome]. Gastroenterol Clin Biol 1985; 9: 65.
92. Jensen RT, Rindi G, Arnold R, et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology 2006; 84: 165.
93. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005; 19: 675.
94. Ling H, Cybulla M, Schaefer O, et al. When to look for von Hippel-Lindau disease in gastroenteropancreatic neuroendocrine tumors? Neuroendocrinology 2004; 80(Suppl. 1): 39.
95. Maki M, Kaneko Y, Ohta Y, et al. Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Intern Med 1995; 34: 661.
96. Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol 2005; 89: 143.
97. Galbut DL, Markowitz AM. Insulinoma: diagnosis, surgical management and long-term follow-up. Review of 41 cases. Am J Surg 1980; 139: 682.
98. Grunberger G, Weiner JL, Silverman R, et al. Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis, treatment, and long-term follow-up. Ann Intern Med 1988; 108: 252.
99. Comi RJ, Gorden P, Doppman JL. Insulinoma. In: Go VLW, Lebenthal E, DiMagno EP, et al. (eds). The Pancreas: Biology, Pathobiology, and Disease, 2nd edn. New York: Raven Press, 1993: 979.
100. Guettier JM, Gorden P. Hypoglycemia. Endocrinol Metab Clin North Am 2006; 35: 753.
101. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249.
102. Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48: 2236.
103. Whipple AO. The surgical therapy of hyperinsulinism. J Int Chir 1938; 3: 237.
104. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 1989; 18: 45.
105. Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332: 1144.
106. Grant CS. Insulinoma. Surg Oncol Clin North Am 1998; 7: 819.
107. Vezzosi D, Bennett A, Fauvel J, et al. Insulin levels measured with an insulin-specific assay in patients with fasting hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol 2003; 149: 413.
108. Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol 2007; 157: 75.
109. Thompson GB, Service FJ, Andrews JC, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 2000; 128: 937.
110. Jensen RT, Norton JA. Endocrine neoplasms of the pancreas. In: Yamada T, Alpers DH, Owyang C, et al. (eds). Atlas of Gastroenterology. Philadelphia: J.B. Lippincott, 1992: 324.
111. Moller DE, Flier JS. Insulin resistance -mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938.
112. Robbins DC, Tager HS, Rubenstein AH. Biologic and clinical importance of proinsulin. N Engl J Med 1984; 310: 1165.
113. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958; 25: 374.
114. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52: 1259.
115. Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology 2006; 6: 155.
116. Jensen RT. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis 1999; 10: 156.
117. Krejs GJ, Walsh JH, Morawski SG, Fordtran JS. Intractable diarrhea. Intestinal perfusion studies and plasma VIP concentrations in patients with pancreatic cholera syndrome and surreptitious ingestion of laxatives and diuretics. Am J Dig Dis 1977; 22: 280.
118. Rambaud JC, Modigliani R, Matuchansky C, et al. Pancreatic cholera. Studies on tumoral secretions and pathophysiology of diarrhea. Gastroenterology 1975; 69: 110.
119. Verner JV, Morrison AB. Non-B islet tumors and the syndrome of watery diarrhea, hypokalemia and hypochlorhydria. Clin Gastroenterol 1974; 3: 595.
120. Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 2008; 12: 382.
121. Dunne MJ, Elton R, Fletcher T, et al. Therapeutic considerations in Sandostatin in the treatment of GEP endocrine tumors. In: O'Dorisio TM (ed.). Sandostatin and Gastroenteropancreatic Endocrine Tumors. Berlin: Springer-Verlag, 1989: 93.
122. Domschke S, Domschke W, Bloom SR, et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 1978; 19: 1049.
123. Go VLW, Korinek JK. Effect of vasoactive intestinal polypeptide on hepatic glucose release. In: Said SI (ed.). Vasoactive Intestinal Peptide. New York: Raven Press, 1982: 231.
124. Bloom SR, Polak JM, Pearse AG. Vasoactive intestinal peptide and water-diarrhoea syndrome. Lancet 1973; 2: 14.
125. Elias E, Polak JM, Bloom SR, et al. Pancreatic cholera due to production of gastric inhibitory polypeptide. Lancet 1972; 2: 791.
126. Tomita T, Kimmel JR, Friesen SR, Mantz FA Jr. Pancreatic polypeptide cell hyperplasia with and without watery diarrhea syndrome. J Surg Oncol 1980; 14: 11.
127. Jaffe BM, Condon S. Prostaglandins E and F in endocrine diarrheagenic syndromes. Ann Surg 1976; 184: 516.
128. Gardner JD, McCarthy DM. VIP and watery diarrhoea I -arguments against VIP being the cause of watery diarrhoea syndrome. In: Bloom SR (ed.). Gut Hormones. Edinburgh: Churchill Livingstone, 1978: 570.
129. Krejs GJ, Kane MG, O'Dorisio TM. VIP and the pancreatic cholera syndrome. N Engl J Med 1984; 310: 1465.
130. Bloom SR. Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera syndrome): value of measurement in diagnosis and treatment. Am J Dig Dis 1978; 23: 373.
131. Kane MG, O'Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med 1983; 309: 1482.
132. Dockray GJ. Vasoactive intestinal polypeptide and related peptides. In: Walsh JH, Dockray GJ (eds). Gut Peptides. New York: Raven Press, 1994: 447.
133. Bloom SR, Christofides ND, Yiangan T. Peptide histidine isoleucine (PHI) and Verner-Morrison syndrome. Gut 1983; 24: 473 [abstract].
134. Bloom SR, Christofides ND, Delamarter J, et al. Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene. Lancet 1983; 2: 1163.
135. Krejs GJ. Comparison of the effect of VIP and PHI on water and ion movement in the canine jejunum in vivo. Gastroenterol Clin Biol 1984; 8: 868 [abstract].
136. Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 1974; 133: 492.
137. Morris AI, Turnberg LA. Surreptitious laxative abuse. Gastroenterology 1979; 77: 780.
138. Garcia CD, Ramos JJ, Guzman de la GF, et al. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 1994; 8: 1563.
139. Liberti A, Bisogno A, Izzo E. Octreotide treatment in secretory and cryptosporidial diarrhea in patients with acquired immunodeficiency syndrome (AIDS): clinical evaluation. J Chemother 1992; 4: 303.
140. Adler G, Lorenz-Meyer H, Martini GA. Sprue syndrome with secretory diarrhoea in a 42-year-old woman. Scand J Gastroenterol Suppl 1981; 70: 175.
141. Babbin BA, Crawford K, Sitaraman SV. Malabsorption work-up: utility of small bowel biopsy. Clin Gastroenterol Hepatol 2006; 4: 1193.
142. Jensen RT. Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome. In: Olbe L (ed.). Milestones in Drug Therapy. Basel: Birkhauser Verlag, 1999: 205.
143. Phillips SF. Surreptitious laxative abuse: keep it in mind. Semin Gastrointest Dis 1999; 10: 132.
144. Fine KD. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116: 1464.
145. Shelton JH, Santa Ana CA, Thompson DR, et al. Factitious diarrhea induced by stimulant laxatives: accuracy of diagnosis by a clinical reference laboratory using thin layer chromatography. Clin Chem 2007; 53: 85.
146. Beyer J, Peters FT, Maurer HH. Screening procedure for detection of stimulant laxatives and/or their metabolites in human urine using gas chromatography-mass spectrometry after enzymatic cleavage of conjugates and extractive methylation. Ther Drug Monit 2005; 27: 151.
147. Schiller LR, Rivera LM, Santangelo WC, et al. Diagnostic value of fasting plasma peptide concentrations in patients with chronic diarrhea. Dig Dis Sci 1994; 39: 2216.
148. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Derm Syph 1942; 45: 1069.
149. McGarvan MH, Unger RH, Recant L, et al. A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med 1966; 274: 1408.
150. Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc 1973; 59: 244.
151. Mallinson CN, Bloom SR, Warin AP, et al. A glucagonoma syndrome. Lancet 1974; 2: 1.
152. Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol 2005; 19: 807.
153. Leichter SB. Clinical and metabolic aspects of glucagonoma. Medicine 1980; 59: 100.
154. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 1981; 2: 347.
155. van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 2004; 151: 531.
156. Pujol RM, Wang CY, el-Azhary RA, et al. Necrolytic migratory erythema: clinicopathologic study of 13 cases. Int J Dermatol 2004; 43: 12.
157. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed 2004; 6: 4.
158. Wald M, Lawrenz K, Luckner D, et al. Glucagon therapy as a possible cause of erythema necrolyticum migrans in two neonates with persistent hyperinsulinaemic hypoglycaemia. Eur J Pediatr 2002; 161: 600.
159. Case CC, Vassilopoulou-Sellin R. Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocr Pract 2003; 9: 22.
160. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol 1998; 38: 866.
161. Norton JA, Kahn CR, Schiebinger R, et al. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med 1979; 91: 213.
162. Sheppard BC, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study. Surgery 1989; 106: 1108.
163. Marynick SP, Fagadau WR, Duncan LA. Malignant glucagonoma syndrome: response to chemotherapy. Ann Intern Med 1980; 93: 453.
164. Jensen RT. Pancreatic endocrine tumors. In: Goldman L, Ausiello D (eds). Cecil Textbook of Medicine, 22nd edn. Philadelphia: Saunders, 2004: 838.
165. Wolfe BM, Culebras JM, Aoki TT, et al. The effects of glucagon on protein metabolism in normal man. Surgery 1979; 86: 248.
166. Boden G, Master RW, Rezvani I, et al. Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. J Clin Invest 1980; 65: 706.
167. Boden G, Rezvani I, Owen OE. Effects of glucagon on plasma amino acids. J Clin Invest 1984; 73: 785.
168. Klein S, Jahoor F, Baba H, et al. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism 1992; 41: 1171.
169. Barazzoni R, Zanetti M, Tiengo A, Tessari P. Protein metabolism in glucagonoma. Diabetologia 1999; 42: 326.
170. Wermers RA, Fatourechi V, Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996; 71: 1030.
171. Maton PN, Gardner JD, Jensen RT. Use of the long-acting somatostatin analog, SMS 201-995, in patients with pancreatic islet cell tumors. Dig Dis Sci 1989; 34: 28S.
172. Jensen PB, Kristensen P, Clausen JT, et al. The hypothalamic satiety peptide CART is expressed in anorectic and non-anorectic pancreatic islet tumors and in normal islet of Langerhans. FEBS Lett 1999; 447: 139.
173. Jensen PB, Blume N, Mikkelsen JD, et al. Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus. J Clin Invest 1998; 101: 503.
174. Boden G, Ryan IG, Eisenschmid BL, et al. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 1986; 314: 1686.
175. Kessinger A, Lemon HM, Foley JF. The glucagonoma syndrome and its management. J Surg Oncol 1977; 9: 419.
176. Naets JP, Guns M. Inhibitory effect of glucagon on erythropoiesis. Blood 1980; 55: 997.
177. Echenique-Elizondo M, Tuneu Valls A, Elorza Orue JL, et al. Glucagonoma and pseudoglucagonoma syndrome. J Pancreas 2004; 5: 179.
178. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg 1996; 20: 203.
179. Kovacs RK, Korom I, Dobozy A, et al. Necrolytic migratory erythema. J Cutan Pathol 2006; 33: 242.
180. Kitamura Y, Sato M, Hatamochi A, Yamazaki S. Necrolytic migratory erythema without glucagonoma associated with hepatitis B. Eur J Dermatol 2005; 15: 49.
181. Technau K, Renkl A, Norgauer J, Ziemer M. Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma. Eur J Dermatol 2005; 15: 110.
182. Nakashima H, Komine M, Sasaki K, et al. Necrolytic migratory erythema without glucagonoma in a patient with short bowel syndrome. J Dermatol 2006; 33: 557.
183. Bak H, Ahn SK. Pseudoglucagonoma syndrome in a patient with malnutrition. Arch Dermatol 2005; 141: 914.
184. Boden G, Owen OE. Familial hyperglucagonemia -an autosomal dominant disorder. N Engl J Med 1977; 296: 534.
185. Palmer JP, Werner PL, Benson JW, Ensinck JW. Dominant inheritance of large molecular weight immunoreactive glucagon. J Clin Invest 1978; 61: 763.
186. Ganda OP, Weir GC, Soeldner JS, et al. Somatostatinoma: a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 1977; 296: 963.
187. Larsson LI, Hirsch MA, Holst JJ, et al. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1977; 1: 666.
188. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med 1979; 301: 285.
189. Schusdziarra V, Grube D, Seifert H, et al. Somatostatinoma syndrome. Clinical, morphological and metabolic features and therapeutic aspects. Klin Wochenschr 1983; 61: 681.
190. Jensen RT. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In: Lewis JH, Dubois A (eds). Current Clinical Topics in Gastrointestinal Pharmacology. Malden, MA: Blackwell Science, 1997: 144.
191. Guillermet-Guibert J, Lahlou H, Cordelier P, et al. Physiology of somatostatin receptors. J Endocrinol Invest 2005; 28(11 Suppl. International): 5.
192. Moayedoddin B, Booya F, Wermers RA, et al. Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocr Pract 2006; 12: 394.
193. Tanaka S, Yamasaki S, Matsushita S, et al. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int 2000; 50: 146.
194. Moschetta A, Stolk MF, Rehfeld JF, et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001; 15: 181.
195. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients -a clinical research center study. J Clin Endocrinol Metab 1995; 80: 2768.
196. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 1997; 79: 830.
197. Samols E, Weir GC, Ramseur R, et al. Modulation of pancreatic somatostatin by adrenergic and cholinergic agonism and by hyper-and hypoglycemic sulfonamides. Metabolism 1978; 27: 1219.
198. Pipeleers D, Couturier E, Gepts W, et al. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab 1983; 56: 1236.
199. Taccagni GL, Carlucci M, Sironi M, et al. Duodenal somatostatinoma with psammoma bodies: an immunohistochemical and ultra-structural study. Am J Gastroenterol 1986; 81: 33.
200. Cappelli C, Agosti B, Braga M, et al. von Recklinghausen's neurofibromatosis associated with duodenal somatostatinoma. A case report and review of the literature. Minerva Endocrinol 2004; 29: 19.
201. Fendrich V, Ramaswamy A, Slater EP, Bartsch DK. Duodenal somatostatinoma associated with Von Recklinghausen's disease. J Hepatobiliary Pancreat Surg 2004; 11: 417.
202. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 1982; 300: 276.
203. Thorner MD, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest 1982; 70: 965.
204. Gola M, Doga M, Bonadonna S, et al. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Pituitary 2006; 9: 221.
205. Bostwick DG, Quan R, Hoffman AR, et al. Growth-hormonereleasing factor immunoreactivity in human endocrine tumors. Am J Pathol 1984; 117: 167.
206. Dayal Y, Lin HD, Tallberg K, et al. Immunocytochemical demonstration of growth hormone-releasing factor in gastrointestinal and pancreatic endocrine tumors. Am J Clin Pathol 1986; 85: 13.
207. Losa M, Schopohl J, von Werder K. Ectopic secretion of growth hormone-releasing hormone in man. J Endocrinol Invest 1993; 16: 69.
208. Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev 1988; 9: 357.
209. Biermasz NR, Smit JW, Pereira AM, et al. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary 2007; 10: 237.
210. Sugihara H, Shibasaki T, Tatsuguchi A, et al. A non-acromegalic case of multiple endocrine neoplasia type 1 accompanied by a growth hormone-releasing hormone-producing pancreatic tumor. J Endocrinol Invest 2007; 30: 421.
211. Thorner MO, Frohman LA, Leong DA, et al. Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: plasma GRF levels in 177 acromegalic patients. J Clin Endocrinol Metab 1984; 59: 846.
212. Eckhauser FE, Cheung PS, Vinik AI, et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986; 100: 978.
213. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243: 265.
214. Kloppel G, Willemar S, Stamm B, et al. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer 1986; 57: 1824.
215. Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984; 8: 561.
216. Plockinger U, Wiedenmann B. Diagnosis of non-functioning neuroendocrine gastro-enteropancreatic tumours. Neuroendocrinology 2004; 80(Suppl. 1): 35.
217. Mannon P, Taylor IL. The pancreatic polypeptide family. In: Walsh JH, Dockray GJ (eds). Gut Peptides. New York: Raven Press, 1994: 341.
218. Guo KJ, Liao HH, Tian YL, et al. Surgical treatment of nonfunctioning islet cell tumor: report of 41 cases. Hepatobiliary Pancreat Dis Int 2004; 3: 469.
219. Venkatesh S, Ordonez NG, Ajani J, et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 1990; 65: 354.
220. Liu TH, Zhu Y, Cui QC, et al. Nonfunctioning pancreatic endocrine tumors. An immunohistochemical and electron microscopic analysis of 26 cases. Pathol Res Pract 1992; 188: 191.
221. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in non-functioning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323.
222. van Eijck CH, Lamberts SW, Lemaire LC, et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996; 224: 119.
223. Jensen RT. Gastrinoma. Bailliere's Clin Gastroenterol 1996; 10: 555.
224. Adrian TE, Uttenthal LO, Williams SJ, Bloom SR. Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med 1986; 315: 287.
225. Lyons DF, Eisen BR, Clark MR, et al. Concurrent Cushing's and Zollinger-Ellison syndromes in a patient with islet cell carcinoma: case report and review of the literature. Am J Med 1984; 76: 729.
226. Doppman JL, Nieman LK, Cutler GB Jr, et al. Adrenocorticotropic hormone-secreting islet cell tumors: Are they always malignant? Radiology 1994; 190: 59.
227. Amikura K, Alexander HR, Norton JA, et al. The role of surgery in the management of ACTH-producing islet cell tumors of the pancreas. Surgery 1995; 118: 1125.
228. Babu AR, Dwarakanathan AA. Cushing's syndrome from ectopic production of corticotropin by a metastatic gastrinoma. Endocr Pract 2003; 9: 229.
229. Park SY, Rhee Y, Youn JC, et al. Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma. Exp Clin Endocrinol Diabetes 2007; 115: 13.
230. Sundaram V, Schuster DP, Falko JM. Unusual manifestations of cushing's syndrome in a multiple endocrine neoplasia type I kindred. Endocr Pract 1998; 4: 190.
231. Miehle K, Tannapfel A, Lamesch P, et al. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab 2004; 89: 3731.
232. Chetty R, Serra S. Spindle cell pancreatic endocrine tumor associated with Cushing's syndrome. Endocr Pathol 2005; 16: 145.
233. Rasbach DA, Hammond JM. Pancreatic islet cell carcinoma with hypercalcemia. Primary hyperparathyroidism or humoral hypercalcemia of malignancy. Am J Med 1985; 78: 337.
234. Van den Eynden GG, Neyret A, Fumey G, et al. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. Bone 2007; 40: 1166.
235. Vacher-Coponat H, Opris A, Denizot A, et al. Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. Nephrol Dial Transplant 2005; 20: 2832.
236. Blackburn AM, Bryant MG, Adrian TE, Bloom SR. Pancreatic tumours produce neurotensin. J Clin Endocrinol Metab 1981; 52: 820.
237. Shulkes A. Neurotensin. In: Walsh JH, Dockray GJ (eds). Gut Peptides: Biochemistry and Physiology. New York: Raven Press, 1994: 371.
238. Orbuch M, Doppman JL, Strader DB, et al. Imaging for pancreatic endocrine tumor localization: recent advances. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research. Basel: Karger, 1995: 268.
239. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatinreceptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004; 36(Suppl. 1): S106.
240. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21: 43.
241. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757.
242. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005; 19: 195.
243. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635.
244. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173.
245. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997; 15: 2420.
246. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin North Am 2003; 12: 231.
247. Zimmer T, Stolzel U, Bader M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39: 562.
248. Norton JA. Surgical treatment of islet cell tumors with special emphasis on operative ultrasound. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers in Gastrointestinal Research. Basel:. Karger, 1995: 309.
249. London JF, Shawker TH, Doppman JL, et al. Zollinger-Ellison syndrome: prospective assessment of abdominal US in the localization of gastrinomas. Radiology 1991; 178: 763.
250. Rothmund M, Angelini L, Brunt LM, et al. Surgery for benign insulinoma: an international review. World J Surg 1990; 14: 393.
251. Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721.
252. Norton JA, Doppman JL, Collen MJ, et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986; 204: 468.
253. Wank SA, Doppman JL, Miller DL, et al. Prospective study of the ability of computerized axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 905.
254. Maton PN, Miller DL, Doppman JL, et al. Role of selective angiography in the management of Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 913.
255. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 229.
256. Pisegna JR, Doppman JL, Norton JA, et al. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 1318.
257. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996; 125: 26.
258. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228.
259. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatinreceptor scintigraphy in gastroenteropancreatic tumors. Ann N Y Acad Sci 1994; 733: 416.
260. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716.
261. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69.
262. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36: 228.
263. Ruszniewski P, Amouyal P, Amouyal G, et al. Endocrine tumors of the pancreatic area: localization by endoscopic ultrasonography. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers in Gastrointestinal Research. Basel: Karger, 1995: 258.
264. Ruszniewski P, Amouyal P, Amouyal G, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629.
265. Zimmer T, Scherübl H, Faiss S, et al. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000; 62(Suppl. 1): 45.
266. McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 177.
267. Cherner JA, Doppman JL, Norton JA, et al. Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med 1986; 105: 841.
268. Miller DL, Doppman JL, Metz DC, et al. Zollinger-Ellison syndrome: technique, results and complications of portal venous sampling. Radiology 1992; 182: 235.
269. Strader DB, Doppman JL, Orbuch M, et al. Functional localization of pancreatic endocrine tumors. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel: Karger, 1995: 282.
270. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995; 123: 269.
271. Norton JA, Cromack DT, Shawker TH, et al. Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg 1988; 207: 160.
272. Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 2001; 136: 1020.
273. Orbuch M, Doppman JL, Jensen RT. Localization of pancreatic endocrine tumors. In: Sleisenger MH, Fordtran JS (eds). Pancreatic Endocrine Tumors (Issue editor Robert T. Jensen). In: Seminars in Gastrointestinal Disease. Duluth, MN: W.B. Saunders Publishing Co, 1995: 90.
274. Breeman WA, Kwekkeboom DJ, de Blois E, et al. Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents Med Chem 2007; 7: 345.
275. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335.
276. Weinel RJ, Neuhaus C, Stapp J, et al. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg 1993; 218: 640.
277. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853.
278. Cadiot G, Bonnaud G, Lebtahi R, et al. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut 1997; 41: 107.
279. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995; 36: 542.
280. Chiti A, Fanti S, Savelli G, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25: 1396.
281. Schillaci O, Spanu A, Scopinaro F, et al. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2003; 23: 1687.
282. Termanini B, Gibril F, Doppman JL, et al. Distinguishing small hepatic hemangiomas from vascular liver metastases in patients with gastrinoma: Use of a somatostatin-receptor scintigraphic agent. Radiology 1997; 202: 151.
283. Varas Lorenzo MJ, Miquel Collell JM, Maluenda C, et al. Preoperative detection of gastrointestinal neuroendocrine tumors using endoscopic ultrasonography. Rev Esp Enferm Dig 2006; 98: 828.
284. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40: 539.
285. Gibril F, Reynolds JC, Roy PK, et al. Ability of somatostatin receptor scintigraphy to identify patients with localized gastric carcinoids: A prospective study. J Nucl Med 2000; 41: 1646.
286. Imamura M, Takahashi K, Isobe Y, et al. Curative resection of multiple gastrinomas aided by selective arterial secretin injection and intraoperative secretin test. Ann Surg 1989; 210: 710.
287. Doppman JL, Miller DL, Chang R, et al. Insulinomas: Localization with selective intraarterial injection of calcium. Radiology 1991; 178: 237.
288. Won JG, Tseng HS, Yang AH, et al. Intra-arterial calcium stimulation test for detection of insulinomas: detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism 2003; 52: 1320.
289. Wiesli P, Brandle M, Schmid C, et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol 2004; 15: 1251.
290. Fernandez-Cruz L, Cesar-Borges G. Laparoscopic strategies for resection of insulinomas. J Gastrointest Surg 2006; 10: 752.
291. Assalia A, Gagner M. Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 2004; 28: 1239.
292. Ayav A, Bresler L, Brunaud L, Boissel P. Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg 2005; 390: 134.
293. Sa Cunha A, Beau C, Rault A, et al. Laparoscopic versus open approach for solitary insulinoma. Surg Endosc 2007; 21: 103.
294. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTATyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508.
295. Eriksson B, Orlefors H, Oberg K, et al. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 311.
296. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392.
297. Metz DC, Jensen RT. Carcinoids and pancreatic endocrine tumors. In: Rustgi AK, Crawford JM (eds). Gastrointestinal Cancers. Philadelphia: W.B. Saunders, 2003: 681.
298. Broder LE, Carter SK. Pancreatic islet cell tumors. I. Clinical features of 52 patients. Ann Intern Med 1973; 79: 101.
299. Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189.
300. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43: 422.
301. Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654.
302. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20: 2633.
303. Pape UF, Bohmig M, Berndt U, et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German Referral Center. Ann N Y Acad Sci 2004; 1014: 222.
304. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083.
305. Gogel HK, Cadieux D, Strickland RG. The use of Boot's secretin in the secretin stimulation test. Gastroenterology 1980; 79: 773.
306. Norton JA, Sugarbaker PH, Doppman JL, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986; 203: 352.
307. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62: 51.
308. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430.
309. Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855.
310. Metz DC, Kuchnio M, Fraker DL, et al. Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology 1993; 105: 799.
311. Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet cell tumors. Surgery 1986; 99: 671.
312. Thompson GB, Van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988; 104: 1011-7.
313. Lo CY, Van Heerden JA, Thompson GB, et al. Islet cell carcinoma of the pancreas. World J Surg 1996; 20: 878.
314. Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220: 320.
315. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244: 410.
316. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36.
317. Goldstone AP, Scott-Coombes DM, Lynn JA. Surgical management of gastrointestinal endocrine tumours. Clin Gastroenterol 1996; 10: 707.
318. Burch PG, McLeskey CH. Anesthesia for patients with insulinoma treatment with oral diazoxide. Anesthesiology 1981; 55: 472.
319. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997; 73: 640.
320. Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg 1986; 10: 586.
321. De Marinis L, Barbarino A. Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet cell tumor. Metabolism 1980; 29: 599.
322. Murakami K, Taniguchi H, Kobayashi T, et al. Suppression of insulin release by calcium antagonist in human insulinoma in vivo and in vitro: its possible role for clinical use. Kobe J Med Sci 1979; 25: 237.
323. Hofeldt FD, Dippe SE, Levin SR, et al. Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes 1974; 23: 192.
324. McArthur KE, Anderson DS, Durbin TE, et al. Clonidine and lidamidine to inhibit watery diarrhea in a patient with lung cancer. Ann Intern Med 1982; 96: 323.
325. Bhaskar Rao M, O'Dorisio TM, Cataland S, et al. Angiotensin II and norepinephrine antagonize the secretory effect of VIP in rat ileum and colon. Peptides 1984; 5: 291.
326. Field M, McColl I. Ion transport in rabbit ileal mucosa. 3. Effects of catecholamines. Am J Physiol 1973; 225: 852.
327. Jaffe BM, Kopen DF, DeSchryver-Kecskemeti K, et al. Indomethacinresponsive pancreatic cholera. N Engl J Med 1977; 297: 817.
328. Albuquerque RH, Owens CW, Bloom SR. A study of vasoactive intestinal polypeptide (VIP) stimulated intestinal fluid secretion in rat and its inhibition by indomethacin. Experientia 1979; 35: 1496.
329. Pandol SJ, Korman LY, McCarthy DM, Gardner JD. Beneficial effect of oral lithium carbonate in the treatment of pancreatic cholera syndrome. N Engl J Med 1980; 302: 1403.
330. Donowitz M, Elta G, Bloom SR, Nathanson L. Trifluoperazine reversal of secretory diarrhea in pancreatic cholera. Ann Intern Med 1980; 93: 284.
331. Smith PL, Field M. In vitro antisecretory effects of trifluoperazine and other neuroleptics in rabbit and human small intestine. Gastroenterology 1980; 78: 1545.
332. Long RG, Bryant MG, Yuille PM, et al. Mixed pancreatic apudoma with symptoms of excess vasoactive intestinal polypeptide and insulin: improvement of diarrhoea with metoclopramide. Gut 1981; 22: 505.
333. Yamashiro Y, Yamamoto K, Sato M. Loperamide therapy in a child with vipoma-associated diarrhoea [letter]. Lancet 1982; 1: 1413.
334. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133.
335. Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl 1986; 119: 54.
336. Harris AG, Kokoris SP, Ezzat S. Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol 1995; 35: 59.
337. Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxford) 1989; 30: 385.
338. Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005; 152: 757.
339. Osei K, O'Dorisio TM. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones. Ann Intern Med 1985; 103: 223.
340. Wulbrand U, Wied M, Zofel P, et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998; 28: 1038.
341. Maton PN, O'Dorisio TM, Howe BA, et al. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985; 312: 17.
342. Maton PN, O'Dorisio T, Malarkey WB, et al. Successful therapy of pancreatic cholera with the long acting somatostatin analogue SMS 201-995: relation between plasma concentrations of drug and clinical and biochemical responses. Scand J Gastroenterol 1986; 21 (Suppl. 119): 181.
343. Schonfeld WH, Elkin EP, Woltering EA, et al. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. Int J Tech Assess Health Care 1996; 14: 514.
344. Appetecchia M, Ferretti E, Carducci M, et al. Malignant glucagonoma. New options of treatment. J Exp Clin Cancer Res 2006; 25: 135.
345. Melmed S, Ziel FH, Braunstein GD, et al. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. J Clin Endocrinol Metab 1988; 67: 395.
346. Moller DE, Moses AC, Jones K, et al. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. J Clin Endocrinol Metab 1989; 68: 499.
347. Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998; 42: 792.
348. Anderson JV, Bloom SR. Neuroendocrine tumours of the gut: longterm therapy with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 1986; 21(Suppl. 119): 115.
349. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003; 63: 2473.
350. Kvols LK, Buck M, Moertel CG, et al. Treatment of metastatic islet cell tumors with somatostatin analogue. Ann Intern Med 1987; 107: 162.
351. Dowling RH, Hussaini SH, Murphy GM, Wass JA. Gallstones during octreotide therapy. Digestion 1993; 54: 107.
352. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279.
353. Roelfsema F, Biermasz NR, Romijn JA, Pereira AM. Treatment strategies for acromegaly. Expert Opin Emerg Drugs 2005; 10: 875.
354. Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother 2005; 6: 2393.
355. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23: 412.
356. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95: 3276.
357. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999; 17: 1111.
358. Norton JA, Alexander HR, Fraker DL, et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495.
359. Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw 2006; 4: 148.
360. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87.
361. Tonelli F, Fratini G, Falchetti A, et al. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med 2005; 257: 38.
362. Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30: 643.
363. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg 2006; 93: 264.
364. Schwartz SS, Horwitz DL, Zehfus B, et al. Continuous monitoring and control of plasma glucose during operation for removal of insulinomas. Surgery 1979; 85: 702.
365. Tutt GO Jr, Edis AJ, Service FJ, Van Heerden JA. Plasma glucose monitoring during operation for insulinoma: a critical reappraisal. Surgery 1980; 88: 351.
366. Chung JC, Choi SH, Jo SH, et al. Localization and surgical treatment of the pancreatic insulinomas. ANZ J Surg 2006; 76: 1051.
367. Grama D, Eriksson B, Martensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16: 632.
368. Chu Q, Al-Kasspooles M, Smith J, et al. Is glucagonoma of the pancreas a curable disease? Int J Gastrointest Cancer 2001; 29: 155.
369. Norton JA, Doherty GD, Fraker DL, et al. Surgical treatment of localized gastrinoma within the liver: A prospective study. Surgery 1998; 124: 1145.
370. Norton JA. Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005; 19: 577.
371. Shepherd JJ, Burgess JR, Greenaway TM, Ware R. Preoperative sestamibi scanning and surgical findings at bilateral, unilateral, or minimal reoperation for recurrent hyperparathyroidism after subtotal parathyroidectomy in patients with multiple endocrine neoplasia type 1. Arch Surg 2000; 135: 844.
372. Plockinger U, Wiedenmann B. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 553.
373. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 131.
374. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 585.
375. Arnold R, Rinke A, Schmidt C, Hofbauer L. Chemotherapy. Best Pract Res Clin Gastroenterol 2005; 19: 649.
376. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458.
377. Niederhuber JE, Fojo T. Treatment of metastatic disease in patients with neuroendocrine tumors. Surg Oncol Clin N Am 2006; 15: 511, viii.
378. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79: 108.
379. Kvols LK, Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 1987; 82: 77.
380. Moertel CG, Lavin PT, Hahn RG. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1982; 66: 1567.
381. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94: 1326.
382. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992; 326: 519.
383. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227.
384. Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32: 203.
385. Kelsen DP, Buckner J, Einzig A, et al. Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep 1987; 71: 329.
386. Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994; 74: 958.
387. Bukowski RM, Tangen C, Lee R, et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1914.
388. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007; 16: 219.
389. Pederzoli P, Falconi M, Bonora A, et al. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol 1999; 31: S207.
390. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62(Suppl. 1): 73.
391. Vilar E, Salazar R, Perez-Garcia J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007; 14: 221.
392. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30: 435.
393. O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80(Suppl. 1): 79.
394. Falconi M, Bettini R, Boninsegna L, et al. Surgical strategy in the treatment of pancreatic neuroendocrine tumors. J Pancreas 2006; 7: 150.
395. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502.
396. Arcenas AG, Ajani JA, Carrasco CH, et al. Vascular occlusive therapy of pancreatic endocrine tumors metastatic to the liver. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel: Karger, 1995: 439.
397. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004; 80(Suppl. 1): 74.
398. Eriksson B, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel: Karger, 1995: 451.
399. Pisegna JR, Slimak GG, Doppman JL, et al. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 1993; 105: 1179.
400. Shah T, Caplin M. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 617.
401. Plockinger U, Wiedenmann B. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 145.
402. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004; 80(Suppl. 1): 85.
403. Maton PN. The use of the long-acting somatostatin analog, octreotide acetate, in patients with islet cell tumors. Gastroenterol Clin North Am 1989; 18: 897.
404. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62: 84.
405. Hoffmann KM, Gibril F, Entsuah LK, et al. Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab 2006; 91: 204.
406. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17: 1733.
407. Delaunoit T, Rubin J, Neczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005; 80: 502.
408. Azoulay D, Bismuth H. Role of liver surgery and transplantation in patients with hepatic metastases from pancreatic endocrine tumors. In: Mignon M, Jensen RT (eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel: Karger, 1995: 461.
409. Routley D, Ramage JK, McPeake J, et al. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transplant Surg 1995; 1: 118.
410. Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997; 225: 347.
411. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31case French multicentric report. Ann Surg 1997; 225: 355.
412. Pascher A, Klupp J, Neuhaus P. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 637.
413. Forrer F, Valkema R, Kwekkeboom DJ, et al. Neuroendocrine tumors.Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 111.
414. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19: 595.
415. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46(Suppl. 1): 62S.
416. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 1993; 22: 941.
417. Strauss GM, Weitzman SA, Aoki TT. Dimethyltriazenoimidazole carboxamide therapy of malignant glucagonoma. Ann Intern Med 1979; 90: 57.
418. Prinz RA, Badrinath K, Banerji M, et al. Operative and chemotherapeutic management of malignant glucagon-producing tumors. Surgery 1981; 90: 713.
419. Awrich AE, Peetz M, Fletcher WS. Dimethyltriazenoimidazole carboxamide therapy of islet cell carcinoma of the pancreas. J Surg Oncol 1981; 17: 321.
420. Herr RR, Jahnke JK, Argoudelis AD. The structure of streptozotocin. J Am Chem Soc 1967; 89: 4808.
421. Weiss RB. Streptozotocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982; 66: 427.
422. Rakieten N, Rakieten ML, Nadkani MV. Studies of the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1969; 29: 91.
423. Murray-Lyon IM, Eddleston AL, Williams R, et al. Treatment of multiple-hormone-producing malignant islet-cell tumor with streptozotocin. Lancet 1968; 2: 895.
424. Johnston TP, McCaleb GS, Montgomery JA. Synthesis of chlorozotocin, the 2-chloroethyl analog of the anticancer antibiotic streptozotocin. J Med Chem 1975; 18: 104.
425. Bukowski RM, McCracken JD, Balcerzak SP, Fabian CJ. Phase II study of chlorozotocin in islet cell carcinoma. A southwest Oncology Group study. Cancer Chemother Pharmacol 1983; 11: 48.
426. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762.
427. Wilde MI, Markham A. Ondansetron: A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996; 52: 773.
428. Bajetta E, Rimassa L, Carnaghi C, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998; 83: 372.
429. di Bartolomeo M, Bajetta E, Bochicchio AM, et al. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 1995; 6: 77.
430. Kapran Y, Bauersfeld J, Anlauf M, et al. Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch 2006; 448: 394.
431. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351.
432. Bajetta E, Procopio G, Ferrari L, et al. Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther 2003; 3: 631.
433. Takahashi H, Nakano K, Adachi Y, et al. Multiple nonfunctional pancreatic islet cell tumor in multiple endocrine neoplasia type I. A case report. Acta Pathol (Jpn) 1988; 38: 667.
434. Fazio N, De BF, Delle FG, Oberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 2007; 18: 13.
435. Öberg K. Interferon in the management of neuroendocrine GEP-tumors. Digestion 2000; 62(Suppl. 1): 92.
436. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687.
437. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multi-center trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689.
438. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761.
439. Papotti M, Bonjiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. Virchows Arch 2002; 440: 461.
440. Nasir A, Stridsberg M, Strosberg J, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 2006; 13: 52.
441. Fjallskog ML, Ludvigsen E, Stridsberg M, et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 59.
442. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 1997; 8: 1041.
443. Panzuto F, Di Francesco V, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006; 17: 461.
444. Marlink RG, Lokich JJ, Robins JR, Clouse ME. Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 1990; 65: 2227.
445. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83: 2293.
446. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 2000; 12: 151.
447. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Related Cancer 2003; 10: 463.
448. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104: 1590.
449. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572.
450. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188: 1201.
451. Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999; 11: 38.
452. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71: 2624.
453. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175: 408.
454. Hanssen LE, Schrumpf E, Kolbenstvedt AN, et al. Treatment of malignant metastatic midgut carcinoid tumors with recombinant human α2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24: 787.
455. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112: 1024.
456. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29.
457. House MG, Cameron JL, Lillemoe KD, et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006; 10: 138.
458. Musunuru S, Chen H, Rajpal S, Stephani N, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006; 141: 1000.
459. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10year experience evaluating predictors of survival. Surgery 2007; 142: 10.
460. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30: 435.
461. Frezza EE. Laparoscopic radiofrequency ablation of solitary hepatic gastrinoma metastases. Dig Dis Sci 2004; 49: 224.
462. Veenendaal LM, Borel R, I, van HR. Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours. Eur J Gastroenterol Hepatol 2006; 18: 89.
463. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 1998; 66: 1307.
464. Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multi-visceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13: 327.
465. Janson ET, Eriksson B, Oberg K, et al. Treatment with high dose [111In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors. Acta Oncol 1999; 38: 373.
466. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12: 683.
467. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754.
468. Yao JC. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 2007; 21: 163.
469. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401.
470. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer 2007; 14: 207.
471. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2007; 12: 253.
472. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95: 1148.
473. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555.
474. Gibril F, Doppman JD, Jensen RT. Comparative analysis of tumor localization techniques for neuroendocrine tumors. Yale J Biol Med 1997; 70: 481.
475. Marion-Audibert AM, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094.